NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Armata Pharmaceuticals, Inc. (ARMP) Stock Analysis

Armata Pharmaceuticals, Inc. (ARMP) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

ARMP

$5.84

+$0.32 (+5.80%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARMP with… →

ARMP Key Statistics

As of Sep 4, 2026
Trading
Open
$5.49
Previous Close
$5.52
Day's Range
5.48–5.87
52-Week Range
2.79–16.34
Volume
48.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.35
Valuation
Market Cap
$217.14M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
39.17
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.29
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$173.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.18M
1-Year Return
+96.63%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
154.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARMP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−7.01%
2025+239.46%
2024−42.90%
2023+161.29%
2022−77.37%
2021+83.89%
2020−8.31%
2019+10.54%
2018−79.21%
2017−77.05%
2016 (partial year)−78.11%

As of September 4, 2026.

ARMP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$173.80M—
2024$0.00−$18.92M—
2023$0.00−$69.05M—
2022$0.00−$36.92M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$31.22M−$173.80M—
2024$0.00—−$42.44M−$18.92M—
2023$0.00—−$40.89M−$69.05M—
2022$0.00—−$36.95M−$36.92M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARMP Valuation vs Biotechnology Median

Median of 656 stocks
MetricARMPBiotechnology medianvs median
P/S ratio39.1715.26157% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Armata Pharmaceuticals, Inc. (ARMP) at $217.14M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 61 employees.

The most recent close on file for ARMP is $5.84, dated September 4, 2026. That is +$0.32 (+5.80%) against the previous close. The 52-week range on file runs from $2.79 to $16.34. The latest close sits 109.32% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $173.80M. Profit margin runs at 0%. Trailing earnings per share are −5.29.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 39.17. On price-to-sales that is 156.65% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.35. Annualized volatility over the trailing 10 years is 110.27%. The trailing one-year price return is +96.63%. Across 10 years the annualized return works out at −30.56%.

Growth & Income

No dividend is on file for ARMP.

Across the complete calendar years on file, 2025 returned +239.46% and 2018 returned −79.21%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −7.01% year to date.

Peer Comparison

Armata Pharmaceuticals, Inc. (ARMP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Armata Pharmaceuticals, Inc. ARMP $217.14M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Armata Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Visit website →